Journal
CELL REPORTS MEDICINE
Volume 4, Issue 4, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrm.2023.101017
Keywords
-
Categories
Ask authors/readers for more resources
Immunocompromised hematology patients respond poorly to COVID-19 vaccination, but robust T cell immunity is induced, regardless of B cell numbers and antibody response. Seropositivity rates increase with each vaccine dose. Hematology patients show prolonged ASCs and skewed Tfh2/17 responses, but their T cell responses are comparable to healthy individuals. Breakthrough infections in vaccinated patients result in higher antibody responses but similar T cell responses to healthy groups.
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vacci-nation. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (-26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and pep-tide-HLA tetramer-specific CD4+/CD8+ T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vacci-nated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available